SCHEMBL5545985

SCHEMBL5545985

CN1C(=O)[N]c2ccc(F)cc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A1 P18405 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GRIA1 P42261 3/20 0.35
GRIA2 P42262 3/20 0.35
GRIA3 P42263 3/20 0.35
GRIA4 P48058 3/20 0.35
L3MBTL1 Q9Y468 3/20 0.33
PARK7 Q99497 2/20 0.33
ATM Q13315 1/20 0.33
DAO P14920 2/20 0.32
HTR7 P34969 1/20 0.31
NISCH Q9Y2I1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5534874 0.85 GRIA2 (0.38) SRD5A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5540195 0.78 LMNA (0.40) SRD5A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5546306 0.77 TSHR (0.38) ALDH1A1KDM4E
SCHEMBL21753084 0.73 CASP1 (0.49) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2354261 0.72 TTR (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL5537220 0.67 NR1H2 (0.40) L3MBTL1ALDH1A1CA1CA2KDM4E
SCHEMBL5537086 0.67 GABRA1 (0.38) SRD5A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5539472 0.67 CA12 (0.44) SRD5A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL26103780 0.66 ALDH1A1 (0.42) GRIA1GRIA2GRIA3GRIA4L3MBTL1
SCHEMBL15094827 0.64 TTR (0.55) SRD5A1PARK7ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SRD5A1 215/4885GABRA1 692/4885GABRG2 1826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.